Tenor Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Tenor Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-143,758	Closed	-$1.45M	–	612
2022 Q4	$1.45M	Hold	143,758	–	–	0.03%	257
2022 Q3	$1.43M	Hold	143,758	–	–	0.03%	334
2022 Q2	$1.42M	Hold	143,758	–	–	0.03%	348
2022 Q1	$1.42M	Hold	143,758	–	–	0.03%	355
2021 Q4	$1.42M	Hold	143,758	–	–	0.03%	353
2021 Q3	$1.4M	Hold	143,758	–	–	0.03%	304
2021 Q2	$1.39M	Sell	143,758 -136,823	-49%	-$1.33M	0.03%	323
2021 Q1	$2.73M	Buy	+280,581	New	+$2.72M	0.07%	201

Tenor Capital Management's BIOT Position: Q1 2023 in Review

Tenor Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 143,758 shares — an estimated $1.45M sold.

Tenor Capital Management first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $2.73M in Q1 2021. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Tenor Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Tenor Capital Management sold 143,758 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $1.45M.
Tenor Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Tenor Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $2.73M in Q1 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Tenor Capital Management's 13F filing for Q1 2023, filed 15 May 2023.